METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models
Journal of Clinical Investigation · 16.11.2026 · 136 (22)
DOI: 10.1172/jci199747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.11.2026. Verfasst von Jiaxi Song und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Sc…. Hauptthemen laut MEDLINE: Cell Differentiation, Lymphocytic Choriomeningitis, Hepatocyte Nuclear Factor 1-alpha, T Follicular Helper Cells. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Priority Research Program of the Chinese Academy of Sciences, Ministry of Science and Technology of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
T follicular helper (T FH ) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling T FH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of T FH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13 hi T FH cells, and its deficiency impaired T FH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key T FH -associated loci, including Cxcr5 and Il6ra . Notably, ginkgolic acid treatment suppressed T FH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during T FH differentiation and suggest that modulation of this pathway may provide a strategy to tune T FH -driven immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Guangzhou National Laboratory, Guangzhou, China.
- Hefei National Research Center for Physical Sciences at the Microscale, Ministry of Education Key Laboratory of Cellular Dynamics, Chinese Academy of Sciences Key Laboratory of Brain Function and Disease, School of Life…
- Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- National Engineering Center for Biochip at Shanghai, Shanghai, China.
Förderung
- Strategic Priority Research Program of the Chinese Academy of Sciences
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- University of Science and Technology of China
- USTC Research Funds of the Double First-Class Initiative
- State Key Laboratory of Immune Response and Immunotherapy 2025
- Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM
Zitieren
APA
Song, J., Cui, D., Wang, J., Qi, X., Ma, J., Yu, H., Liu, Q., Yang, J., Hu, T., Han, X., Ma, H., Yu, R., Dai, Y., Zhang, X., Cao, Q., Song, X., Li, B., Ye, L., Wang, H., …, & Li, F. (2026). METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models. Journal of Clinical Investigation, 136(22). https://doi.org/10.1172/jci199747
Vancouver
Song J, Cui D, Wang J, Qi X, Ma J, Yu H, et al. METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models. Journal of Clinical Investigation. 2026;136(22). doi:10.1172/jci199747
BibTeX
@article{Song2026,
author = {Song, Jiaxi and Cui, Dan and Wang, Jiabao and Qi, Xuewei and Ma, Jiaxin and Yu, Haoyu and Liu, Qing and Yang, Jing and Hu, Tengfei and Han, Xu and Ma, Handong and Yu, Rentao and Dai, Ying and Zhang, Xiaona and Cao, Qunfa and Song, Xiaoyuan and Li, Bofeng and Ye, Lilin and Wang, Hua and Huang, Qizhao and Li, Jia and Li, Fengyin},
title = {METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {22},
doi = {10.1172/jci199747}
}
EUVIMED